Ranexa Tablets Must NOT Be Crushed
Ranexa (ranolazine) tablets should be swallowed whole and must never be crushed, broken, or chewed 1. This is explicitly stated in the FDA-approved prescribing information and patient counseling guidelines.
Why Crushing Is Contraindicated
Ranexa is formulated as an extended-release tablet designed to deliver ranolazine over a prolonged period 2. The extended-release mechanism is critical to:
- Maintain therapeutic drug levels throughout the dosing interval
- Minimize peak-to-trough fluctuations that could increase adverse effects
- Ensure the drug's concentration-dependent effects on late sodium current inhibition occur safely 2
Crushing the tablet destroys the extended-release matrix, resulting in immediate release of the entire dose. This creates several serious risks:
Safety Concerns with Crushing
QT Interval Prolongation: Ranolazine causes dose-dependent QTc prolongation 1. Crushing releases the full dose immediately, potentially causing dangerous QT prolongation and increasing proarrhythmic risk.
Loss of Therapeutic Effect: The extended-release formulation was specifically developed after the immediate-release formulation showed "conflicting results" in clinical efficacy 2. Only the extended-release formulation (500 mg or 1000 mg twice daily) has proven effectiveness for chronic stable angina 2.
Increased Adverse Effects: Immediate drug release increases peak plasma concentrations, raising the risk of dizziness, nausea, and other dose-related side effects that already cause 6% of patients to discontinue therapy 1.
Clinical Implications
- No alternative formulations exist: Ranexa is only available as extended-release tablets 1
- Patients with swallowing difficulties: If a patient cannot swallow tablets whole, ranolazine is not an appropriate medication choice 3
- Alternative antianginal agents should be considered for patients requiring crushed medications (e.g., sublingual nitrates, transdermal patches, or other agents available in alternative formulations)
Common Pitfall to Avoid
Do not assume that splitting or crushing medications is acceptable to reduce costs or ease administration without verifying the formulation type 3. Extended-release medications like Ranexa require intact tablet structure to function safely and effectively.